FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3042185315> ?p ?o ?g. }

• W3042185315 endingPage "104382" @default.
• W3042185315 startingPage "104382" @default.
• W3042185315 abstract "The incidence of invasive aspergillosis (IA) has dramatically increased during the last decade. This infection is associated with high morbidity and mortality, ranging from 30% to 70%, especially in immunocompromised patients. Delay in diagnosis and treatment is usually associated with high mortality rates. This study was aimed to assess the diagnostic value of Galactomannan EIA (GM) for early diagnosis of aspergillosis in hospitalized patients with underlying conditions. Also, the antifungal drug susceptibility profiles of causative agents were investigated. In this descriptive cross-sectional study, during the period of 18 months starting from September 2017 until February 2019, 22 bronchoalveolar lavage (BAL) and 13 biopsies from infected sinuses were obtained from a total of 150 patients suffering from different types of hematologic malignancies. All the samples were subjected to microscopic examination and fungal culture. Also, serum specimens were obtained from all patients (n = 135). 22 serum and 17 BAL specimens were tested for the GM level. Fungal identified were confirmed through the PCR-sequencing of the β-tubulin gene. The susceptibility to amphotericin B, itraconazole, voriconazole, posaconazole, ravuconazole, and caspofungin was evaluated according to the Clinical and Laboratory Standards Institute document M38-A2 (CLSI M38-A2) broth microdilution protocol. The results showed that the incident rate of IA was 23.33% and 35 patients with IA (12 proven cases and 23 probable cases) were diagnosed according to the European Organization for Research and Treatment of Cancer and Mycoses Study Group criteria. The 35 patients with IA in the current study comprised 19 men (54.29%) and 16 women (45.71%) with the median age of 42 years. AML (31.5%) was documented as the most prevalent risk factor among our subjects with IA and Aspergillus flavus (65.7%) was the most prevailing causal agent in this study. Among patients with IA, ague (71%) and cough (60%) were the most common symptoms. In the present study, a sensitivity of 94% and a specificity of 98% was reported for GM ELISA in BAL specimens. Also, a sensitivity of 58% and a specificity of 98% was reported for GM ELISA in serum samples. Among 6 tested antifungal drugs, the lowest minimum inhibitory concentration (MIC) values were observed for posaconazole and ravuconazole which showed the range of 0.008–0.0062 μgml and 0.031–0.125 μgml, respectively. The current study has demonstrated that determining the value of GM investigation in BAL and serum specimens can be promising in early diagnosis of IA, also molecular identification of the agents causing IA and their antifungal susceptibility patterns are essential issues for the targeted antifungal therapy and outcome improvement of patients with this life-threatening disease." @default.
• W3042185315 created "2020-07-16" @default.
• W3042185315 creator A5009180721 @default.
• W3042185315 creator A5023505145 @default.
• W3042185315 creator A5028557002 @default.
• W3042185315 creator A5031951813 @default.
• W3042185315 creator A5039509872 @default.
• W3042185315 creator A5042559457 @default.
• W3042185315 creator A5055218922 @default.
• W3042185315 creator A5056548905 @default.
• W3042185315 creator A5061591971 @default.
• W3042185315 creator A5067590500 @default.
• W3042185315 creator A5067754756 @default.
• W3042185315 creator A5071139058 @default.
• W3042185315 date "2020-10-01" @default.
• W3042185315 modified "2023-10-11" @default.
• W3042185315 title "Study on invasive aspergillosis using galactomannan enzyme immunoassay and determining antifungal drug susceptibility among hospitalized patients with hematologic malignancies or candidates for organ transplantation" @default.
• W3042185315 cites W111826357 @default.
• W3042185315 cites W1774456129 @default.
• W3042185315 cites W1974435419 @default.
• W3042185315 cites W1980313403 @default.
• W3042185315 cites W1982478538 @default.
• W3042185315 cites W2001579789 @default.
• W3042185315 cites W2009231367 @default.
• W3042185315 cites W2014188602 @default.
• W3042185315 cites W2017212369 @default.
• W3042185315 cites W2039267791 @default.
• W3042185315 cites W2047888924 @default.
• W3042185315 cites W2054453138 @default.
• W3042185315 cites W2056588716 @default.
• W3042185315 cites W2065295122 @default.
• W3042185315 cites W2068818405 @default.
• W3042185315 cites W2082695689 @default.
• W3042185315 cites W2085145416 @default.
• W3042185315 cites W2098438303 @default.
• W3042185315 cites W2104445943 @default.
• W3042185315 cites W2108824619 @default.
• W3042185315 cites W2123454450 @default.
• W3042185315 cites W2131533910 @default.
• W3042185315 cites W2132135798 @default.
• W3042185315 cites W2149787296 @default.
• W3042185315 cites W2150475740 @default.
• W3042185315 cites W2151085150 @default.
• W3042185315 cites W2158672061 @default.
• W3042185315 cites W2160799773 @default.
• W3042185315 cites W2162347802 @default.
• W3042185315 cites W2164049808 @default.
• W3042185315 cites W2166972217 @default.
• W3042185315 cites W2167506258 @default.
• W3042185315 cites W2170224877 @default.
• W3042185315 cites W2565103680 @default.
• W3042185315 cites W2788683233 @default.
• W3042185315 cites W4244089392 @default.
• W3042185315 cites W4249751692 @default.
• W3042185315 doi "https://doi.org/10.1016/j.micpath.2020.104382" @default.
• W3042185315 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32663605" @default.
• W3042185315 hasPublicationYear "2020" @default.
• W3042185315 type Work @default.
• W3042185315 sameAs 3042185315 @default.
• W3042185315 citedByCount "14" @default.
• W3042185315 countsByYear W30421853152021 @default.
• W3042185315 countsByYear W30421853152022 @default.
• W3042185315 countsByYear W30421853152023 @default.
• W3042185315 crossrefType "journal-article" @default.
• W3042185315 hasAuthorship W3042185315A5009180721 @default.
• W3042185315 hasAuthorship W3042185315A5023505145 @default.
• W3042185315 hasAuthorship W3042185315A5028557002 @default.
• W3042185315 hasAuthorship W3042185315A5031951813 @default.
• W3042185315 hasAuthorship W3042185315A5039509872 @default.
• W3042185315 hasAuthorship W3042185315A5042559457 @default.
• W3042185315 hasAuthorship W3042185315A5055218922 @default.
• W3042185315 hasAuthorship W3042185315A5056548905 @default.
• W3042185315 hasAuthorship W3042185315A5061591971 @default.
• W3042185315 hasAuthorship W3042185315A5067590500 @default.
• W3042185315 hasAuthorship W3042185315A5067754756 @default.
• W3042185315 hasAuthorship W3042185315A5071139058 @default.
• W3042185315 hasConcept C126322002 @default.
• W3042185315 hasConcept C16005928 @default.
• W3042185315 hasConcept C203014093 @default.
• W3042185315 hasConcept C2776391196 @default.
• W3042185315 hasConcept C2777071850 @default.
• W3042185315 hasConcept C2777714996 @default.
• W3042185315 hasConcept C2777961210 @default.
• W3042185315 hasConcept C2778566413 @default.
• W3042185315 hasConcept C2779548794 @default.
• W3042185315 hasConcept C2779629538 @default.
• W3042185315 hasConcept C2780402444 @default.
• W3042185315 hasConcept C2780690907 @default.
• W3042185315 hasConcept C2780782397 @default.
• W3042185315 hasConcept C2991737395 @default.
• W3042185315 hasConcept C71924100 @default.
• W3042185315 hasConcept C90924648 @default.
• W3042185315 hasConceptScore W3042185315C126322002 @default.
• W3042185315 hasConceptScore W3042185315C16005928 @default.
• W3042185315 hasConceptScore W3042185315C203014093 @default.
• W3042185315 hasConceptScore W3042185315C2776391196 @default.
• W3042185315 hasConceptScore W3042185315C2777071850 @default.
• W3042185315 hasConceptScore W3042185315C2777714996 @default.

• next